Literature DB >> 11556548

Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas.

L Kluwe1, C Hagel, M Tatagiba, S Thomas, D Stavrou, H Ostertag, A von Deimling, V F Mautner.   

Abstract

Pilocytic astrocytomas classified as WHO grade I typically arise in childhood and upon complete surgical removal carry a favorable prognosis. Children with neurofibromatosis 1 (NF1) have a vastly increased risk for pilocytic astrocytomas, especially for those of the optic nerve. Using 4 intragenic NF1 microsatellite markers, we examined losses of NF1 alleles on the long arm of chromosome 17 in 12 NF1-associated and 25 sporadic pilocytic astrocytomas. The TP53 gene region on the short arm of chromosome 17 was also examined in these tumors using 3 markers. Loss of 1 NF1 allele was detected in 11 of 12 (92%) informative NF1-associated pilocytic astrocytomas. In contrast, only 1 of 24 informative (4%) sporadic pilocytic astrocytomas exhibited allelic loss in the NF1 region. Among the 11 NF1-associated tumors with NF1 loss, 5 had also lost alleles on 17p. The high rate of NF1 allele loss in NF1-associated pilocytic astrocytomas suggests a tumor initiating or promoting action of the NF1 gene in these patients. On the other hand, the much lower rate of NF1-allele loss in sporadic pilocytic astrocytomas argues for only minor importance of NF1 in that patient group. The present data support different mechanisms in the formation of NF1-associated and sporadic pilocytic astrocytomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11556548     DOI: 10.1093/jnen/60.9.917

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  37 in total

Review 1.  Brain tumours: classification and genes.

Authors:  V P Collins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

2.  CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.

Authors:  Tao Sun; Scott M Gianino; Erin Jackson; David Piwnica-Worms; David H Gutmann; Joshua B Rubin
Journal:  J Neuroimmunol       Date:  2010-07-27       Impact factor: 3.478

3.  Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target.

Authors:  Marianne Hütt-Cabezas; Matthias A Karajannis; David Zagzag; Smit Shah; Iren Horkayne-Szakaly; Elisabeth J Rushing; J Douglas Cameron; Deepali Jain; Charles G Eberhart; Eric H Raabe; Fausto J Rodriguez
Journal:  Neuro Oncol       Date:  2013-11-06       Impact factor: 12.300

4.  An 80-year experience with optic nerve glioma cases at the Armed Forces Institute of Pathology: evolution from museum to molecular evaluation suggests possibe interventions in the cellular senescence and microglial pathways (an American Ophthalmological Society thesis).

Authors:  J Douglas Cameron; Fausto J Rodriguez; Elisabeth Rushing; Iren Horkayne-Szakaly; Charles Eberhart
Journal:  Trans Am Ophthalmol Soc       Date:  2014

Review 5.  The molecular biology of WHO grade I astrocytomas.

Authors:  Nicholas F Marko; Robert J Weil
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

Review 6.  Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma.

Authors:  David H Gutmann
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

Review 7.  Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research.

Authors:  Robert A Avery; Rosalie E Ferner; Robert Listernick; Michael J Fisher; David H Gutmann; Grant T Liu
Journal:  J Neurooncol       Date:  2012-07-28       Impact factor: 4.130

Review 8.  Spinal cord tumours: advances in genetics and their implications for treatment.

Authors:  Patricia L Zadnik; Ziya L Gokaslan; Peter C Burger; Chetan Bettegowda
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

9.  Gliomas in children.

Authors:  Jane E Minturn; Michael J Fisher
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

Review 10.  Molecular neuropathology of gliomas.

Authors:  Markus J Riemenschneider; Guido Reifenberger
Journal:  Int J Mol Sci       Date:  2009-01-07       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.